We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL.
- Authors
Amengual, J. E.; Reagan, P.; Li, H.; Saeed, H.; Vaidya, R.; Unger, J. M.; Danilov, A.; LeBlanc, M.; Friedberg, J. W.; Smith, S. M.
- Abstract
Funding: NIH/NCI/NCTN grants U10CA180888/U10CA180819. Following a safety run-in of 12 patients per each experimental arm, the randomized Phase II study will enroll 180 patients to Arm 1: tafa-len + tazemetostat; Arm 2: tafa-len (control); or Arm 3: tafa-len + zanubrutinib (Figure 1). S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB-LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL.
- Subjects
TRANSPLANTATION of organs, tissues, etc.; PATIENT reported outcome measures
- Publication
Hematological Oncology, 2023, Vol 41, p842
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3166_OT22